MARK RICHMAN: Open Payments
NPI 1124000963 · ADAMSVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,798 in 118 payments from 21 companies in 2025. Trend: 2023 $2,471 · 2024 $2,435 · 2025 $2,798
Food & beverage: $2,786Education: $11
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 21 | $714 |
| Novo Nordisk Inc | 15 | $411 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $228 |
| GlaxoSmithKline, LLC. | 10 | $202 |
| Sumitomo Pharma America, Inc. | 8 | $195 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $151 |
| Corcept Therapeutics | 7 | $145 |
| Dexcom, Inc. | 7 | $129 |
| Paratek Pharmaceuticals, Inc. | 7 | $105 |
| Amgen Inc. | 4 | $89 |
Products named: Ozempic, BREZTRI, FARXIGA, JARDIANCE, TRELEGY ELLIPTA, GEMTESA, Kerendia, Korlym.
Industry payments across AL — which companies pay providers there.
